Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Semaglutide improves health-related quality of life vs placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Experience of family function, family involvement, and self-management in adult patients with type 2 diabetes: A thematic analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIM: To assess what drives change in health-related quality of life (HRQoL) in type 2 diabetes in the SUSTAIN 6 trial and identify potential mediators of the treatment effect of semaglutide on HRQoL scores.

METHODS: The SF-36v2® questionnaire (comprising physical component summary [PCS] and mental component summary [MCS]) was used to assess changes in HRQoL from baseline to week 104, by treatment, in a prespecified analysis. This post hoc analysis assessed change in PCS and MCS using the following factors as parameter/covariate, using descriptive statistics and linear regressions: major adverse cardiac events, hypoglycaemia, gastrointestinal adverse events, at least one episode of nausea, vomiting or diarrhoea, and change in HbA1c , body weight, blood pressure, heart rate and estimated glomerular filtration rate.

RESULTS: Mean change in overall PCS score was +1.0 with semaglutide vs +0.4 with placebo, and +0.5 vs -0.2 for MCS. The treatment effect of semaglutide vs placebo (unadjusted estimate) was 0.7; ([95% confidence interval 0.1;1.2]; p=0.018) on PCS and this was reduced when adjusted for change in HbA1c (0.4; [-0.2;1.0], p=0.167) and body weight (0.3; [-0.3;0.9], p=0.314). The unadjusted treatment effect on MCS (0.7 [-0.0;1.5], p=0.054) was only reduced when adjusted for change in HbA1c (0.3; [-0.4;1.1], p=0.397). When adjusting for all other parameters separately, the estimated effect of semaglutide on PCS and MCS qualitatively did not change.

CONCLUSIONS: Semaglutide improved HRQoL vs placebo; greater improvements with semaglutide vs placebo were possibly mediated, in part, by change in HbA1c and body weight. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
ISSN1462-8902
DOIs
Publication statusE-pub ahead of print - 30 Mar 2020

ID: 59633801